Healthcare >> CEO Interviews >> May 3, 2004
DR. STEPHEN HILL joined ArQule, Inc., as President and Chief Executive
Officer on April 1, 1999. Dr. Hill served as the Head of Global Drug
Development at F. Hoffmann-La Roche Ltd. from 1997. He joined Roche in
1989 as Medical Adviser to Roche Products in the United Kingdom. He held
several senior positions there, including that of Medical Director, with
responsibility for clinical trials of compounds across a broad range of
therapeutic areas, including those of CNS, HIV, cardiovascular,
metabolic, and oncology products. Subsequently, he served as Head of
International Drug Regulatory Affairs at Roche headquarters in Basel,
Switzerland, where he led the regulatory submissions for seven major new
chemical entities globally. He also was a member of Roche's Portfolio
Management, Research, Development and Pharmaceutical Division Executive
Boards. Prior to Roche, Dr. Hill served for seven years with the
National Health Service in the United Kingdom in general and orthopedic
surgery. Dr. Hill is a Fellow of the Royal College of Surgeons of
England and holds his scientific and medical degrees from St.
Catherine's College at Oxford University. Profile
company is today in terms of its development?
Mr. Hill: ArQule is a biotechnology company with a focus on oncology.
